secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-08-06T11:15:15+00:00
Accession:  0001104659-26-091629
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing
--------------------------------------------------------------------------------

- Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.
- Cash, equivalents and marketable securities $170.6M at June 30, 2026; subsequent ATM raised $40.2M gross from 7.3M shares.
- Phase 1a SAD/MAD data for ATI-052 (anti-TSLP/IL-4Rα bispecific) shows favorable safety and potential for quarterly dosing.
- Top line results expected H2 2026 from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, and Phase 2 trial of bosakitug in AD.
- Plan to initiate Phase 2b program for ATI-052 and Phase 2b trial of modzatinib in lichen planus in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/0001104659-26-091629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer